After finishing at $19.27 in the prior trading day, Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $19.61, up 1.76%. In other words, the price has increased by $+0.34 from its previous closing price. On the day, 776419 shares were traded.
Ratios:
Our goal is to gain a better understanding of VRDN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.93 and its Current Ratio is at 13.93. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
On June 14, 2023, BTIG Research started tracking the stock assigning a Buy rating and target price of $46.
On May 30, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $44.RBC Capital Mkts initiated its Outperform rating on May 30, 2023, with a $44 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 22 when Fairmount Funds Management LLC bought 476,190 shares for $21.00 per share. The transaction valued at 9,999,990 led to the insider holds 1,839,954 shares of the business.
Meisner Lara sold 27 shares of VRDN for $765 on Jun 16. The Chief Legal Officer now owns 29,971 shares after completing the transaction at $28.35 per share. On Jun 15, another insider, Meisner Lara, who serves as the Chief Legal Officer of the company, sold 2,269 shares for $28.02 each. As a result, the insider received 63,577 and left with 29,971 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1.17B and an Enterprise Value of 1.01B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2946.54 while its Price-to-Book (P/B) ratio in mrq is 5.76. Its current Enterprise Value per Revenue stands at 2.92k whereas that against EBITDA is -4.71.
Stock Price History:
Over the past 52 weeks, VRDN has reached a high of $33.69, while it has fallen to a 52-week low of $10.93. The 50-Day Moving Average of the stock is 20.31, while the 200-Day Moving Average is calculated to be 19.24.
Shares Statistics:
The stock has traded on average 932.54K shares per day over the past 3-months and 767.03k shares per day over the last 10 days, according to various share statistics. A total of 52.59M shares are outstanding, with a floating share count of 45.67M. Insiders hold about 13.16% of the company’s shares, while institutions hold 108.29% stake in the company. Shares short for VRDN as of Jan 31, 2024 were 8.42M with a Short Ratio of 9.03, compared to 8.65M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 14.10% and a Short% of Float of 14.44%.
Earnings Estimates
Its stock is currently analyzed by 13 different market analysts. On average, analysts expect EPS of -$1 for the current quarter, with a high estimate of -$0.84 and a low estimate of -$1.17, while EPS last year was -$1.13. The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.81 and low estimates of -$1.02.
Analysts are recommending an EPS of between -$4.68 and -$5.15 for the fiscal current year, implying an average EPS of -$4.94. EPS for the following year is -$4.18, with 13 analysts recommending between -$3.26 and -$5.69.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for VRDN’s current fiscal year. The highest revenue estimate was $1M, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $380k. In the same quarter a year ago, actual revenue was $1.77M, down -78.60% from the average estimate.
